keyword
MENU ▼
Read by QxMD icon Read
search

psoriasis treatment

keyword
https://www.readbyqxmd.com/read/27920684/worsening-of-lymphopenia-during-apremilast-treatment
#1
Antonios G A Kolios, Lars E French, Alexander A Navarini
Apremilast is an oral phosphodiesterase IV inhibitor recently registered for the treatment of psoriasis and psoriatic arthritis in Switzerland and other countries. Even though it offers only moderate efficacy compared to biologics, many patients prefer drugs given by the oral route. Apremilast is frequently used in private practice, as it showed no relevant safety signals in clinical trials and often, laboratory tests are omitted completely. Here we report a patient who developed acute lymphopenia and worsening of psoriasis during apremilast treatment, which resolved with discontinuation of apremilast...
September 2016: Case Reports in Dermatology
https://www.readbyqxmd.com/read/27920272/mcpip1-regnase-1-restricts-il-17a-and-il-17c-dependent-skin-inflammation
#2
Leticia Monin, Johann E Gudjonsson, Erin E Childs, Nilesh Amatya, Xianying Xing, Akash H Verma, Bianca M Coleman, Abhishek V Garg, Meaghan Killeen, Alicia Mathers, Nicole L Ward, Sarah L Gaffen
The IL-17 family cytokines IL-17A and IL-17C drive the pathogenesis of psoriatic skin inflammation, and anti-IL-17A Abs were recently approved to treat human psoriasis. Little is known about mechanisms that restrain IL-17 cytokine-mediated signaling, particularly IL-17C. In this article, we show that the endoribonuclease MCP-1-induced protein 1 (MCPIP1; also known as regnase-1) is markedly upregulated in human psoriatic skin lesions. Similarly, MCPIP1 was overexpressed in the imiquimod (IMQ)-driven mouse model of cutaneous inflammation...
December 5, 2016: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/27917632/-early-diagnosis-of-spondyloarthritis
#3
Kristýna Grobelná, Heřman Mann
Spondyloarthritides are chronic inflammatory rheumatic diseases which affect the axial skeleton and/or peripheral joints and have a strong association with HLA-B27 antigen. According to the prevailing symptoms spondyloarthritis can be further divided into predominantly axial or peripheral form.This disease can gradually destroy affected joints with increasing delay between the onset of first symptoms and treatment commencement, therefore early diagnosis and treatment are necessary. Thus, we need to create simple reference strategies to enable primary care physicians effectively identify and refer these patients to a rheumatologist...
2016: Casopís Lékar̆ů C̆eských
https://www.readbyqxmd.com/read/27914574/biological-therapies-immunomodulatory-drugs-worsening-of-psoriasis-and-rebound-effect-new-evidence-of-similitude
#4
REVIEW
Marcus Zulian Teixeira
BACKGROUND: Employing the secondary action or adaptative reaction of the organism as therapeutic response, homeopathy uses the treatment by similitude (similia similibus curentur) administering to sick individuals the medicines that caused similar symptoms in healthy individuals. Such homeostatic or paradoxical reaction of the organism is scientifically explained through the rebound effect of drugs, which cause worsening of symptoms after withdrawal of several palliative treatments. Despite promoting an improvement in psoriasis at the beginning of the treatment, modern biological therapies provoke worsening of the psoriasis (rebound psoriasis) after discontinuation of drugs...
November 2016: Homeopathy: the Journal of the Faculty of Homeopathy
https://www.readbyqxmd.com/read/27910156/ixekizumab-treatment-improves-fingernail-psoriasis-in-patients-with-moderate-to-severe-psoriasis-results-from-the-randomized-controlled-and-open-label-phases-of-uncover-3
#5
P van de Kerkhof, L Guenther, A B Gottlieb, M Sebastian, J J Wu, P Foley, A Morita, O Goldblum, L Zhang, J Erickson, S Ball, P Rich
BACKGROUND: Fingernail psoriasis is difficult to treat. OBJECTIVE: The objective was to evaluate the effect of ixekizumab, a monoclonal antibody selectively targeting IL-17A, on fingernail psoriasis. METHODS: This Phase 3, double-blind trial (UNCOVER-3) randomized patients to placebo, etanercept (50-mg twice weekly), or 80 mg ixekizumab as one injection every 4 (IXE Q4W) or 2 weeks (IXE Q2W) after a 160-mg starting dose. At Week 12, ixekizumab patients received open-label IXE Q4W through Week 60; placebo patients received a 160-mg starting ixekizumab dose and etanercept patients a 4-week placebo washout before starting IXE Q4W...
November 5, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27909086/the-12-item-psoriatic-arthritis-impact-of-disease-questionnaire-construct-validity-reliability-and-interpretability-in-a-clinical-setting
#6
Marco Di Carlo, Andrea Becciolini, Valentina Lato, Chiara Crotti, Ennio Giulio Favalli, Fausto Salaffi
OBJECTIVE: To study, in a real-life setting, the construct validity, the reliability, and the interpretability of the 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) questionnaire in patients with psoriatic arthritis (PsA). METHODS: In 144 consecutive patients with PsA (81 men and 63 women, mean age of 51.4 ± 12.8 yrs, and 77 receiving biologic treatment), the PsAID-12 and other patient-reported outcomes (PRO) were collected, such as the Dermatology Life Quality Index...
December 1, 2016: Journal of Rheumatology
https://www.readbyqxmd.com/read/27908543/from-the-medical-board-of-the-national-psoriasis-foundation-treatment-targets-for-plaque-psoriasis
#7
April W Armstrong, Michael P Siegel, Jerry Bagel, Erin E Boh, Megan Buell, Kevin D Cooper, Kristina Callis Duffin, Lawrence F Eichenfield, Amit Garg, Joel M Gelfand, Alice B Gottlieb, John Y M Koo, Neil J Korman, Gerald G Krueger, Mark G Lebwohl, Craig L Leonardi, Arthur M Mandelin, M Alan Menter, Joseph F Merola, David M Pariser, Ronald B Prussick, Caitriona Ryan, Kara N Shah, Jeffrey M Weinberg, MaryJane O U Williams, Jashin J Wu, Paul S Yamauchi, Abby S Van Voorhees
BACKGROUND: An urgent need exists in the United States to establish treatment goals in psoriasis. OBJECTIVE: We aim to establish defined treatment targets toward which clinicians and patients with psoriasis can strive to inform treatment decisions, reduce disease burden, and improve outcomes in practice. METHODS: The National Psoriasis Foundation conducted a consensus-building study among psoriasis experts using the Delphi method. The process consisted of: (1) literature review, (2) pre-Delphi question selection and input from general dermatologists and patients, and (3) 4 Delphi rounds...
November 22, 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27905011/under-treatment-of-patients-with-moderate-to-severe-psoriasis-in-the-united-states-analysis-of-medication-usage-with-health-plan-data
#8
April W Armstrong, J Will Koning, Simon Rowse, Huaming Tan, Carla Mamolo, Mandeep Kaur
INTRODUCTION: Psoriasis is a chronic inflammatory disorder with significant morbidity and mortality, but a persistent gap appears to exist for the adequate treatment of patients with moderate to severe disease. As the extent of under-treatment is unknown, we attempted to determine overall treatment patterns and estimate under-treatment using a large database. METHODS: Data from the US National Health and Wellness Survey was used to estimate the proportion of patients with mild, moderate or severe psoriasis...
November 30, 2016: Dermatology and Therapy
https://www.readbyqxmd.com/read/27904275/hidden-pictures-of-kaposi-s-sarcoma-in-psoriatic-lesions-a-diagnostic-challenge
#9
Jisook Yoo, Mingyul Jo, Min-Soo Kim, Kwang-Hyun Choi, Hyang-Joon Park, Mihn-Sook Jue
Kaposi's sarcoma is a multifocal proliferative vascular tumor involving the skin and other organ and psoriasis is a chronic cutaneous disease with papules and plaques with white scale. Development of Kaposi's sarcoma in psoriasis patients has been reported rarely. A 71-year-old man presented with multiple brownish to violaceous plaques on both feet and arms which were found 4 months ago. The biopsy confirmed Kaposi's sarcoma. The patient was diagnosed with psoriasis vulgaris 10 years ago and Kaposi's sarcoma lesions developed between psoriatic plaques...
December 2016: Annals of Dermatology
https://www.readbyqxmd.com/read/27904187/the-relationship-of-psoriasis-and-melanocytic-nevi
#10
Fatma Pelin Cengiz, Nazan Emiroglu, Anil Gulsel Bahali, Dilek Biyik Ozkaya, Ozlem Su, Nahide Onsun
BACKGROUND: There is limited data about the relationship between psoriasis and melanocytic lesions and melanoma. Immunologic pathways which were implicated in psoriasis induce a reduction in the number of melanocytic nevi. AIMS AND OBJECTIVES: To investigate the number of melanocytic nevi in psoriatic patients compared with controls and its relationship with disease severity and type of treatment. METHODS: We performed a prospective study in 100 psoriatic patients and 100 controls...
November 2016: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/27900946/childhood-psoriasis
#11
Emmanuel Mahé
Psoriasis is a common chronic inflammatory skin disease. Recently, few data have been published on epidemiology, comorbidity, or therapy in children with psoriasis. Psoriasis affects up to 2% of children in Europe, even during the first months of life. The link between psoriasis and metabolic comorbidities has been highlighted, notably in relation to excessive weight and obesity. The clinical picture of psoriasis in childhood resembles adult disease, however, some clinical features are noteworthy: neonatal diaper rash is relatively specific, face involvement and guttate psoriasis are more common, plaques are often smaller, and scales are finer and softer than in adults...
November 29, 2016: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/27895471/adherence-satisfaction-and-preferences-for-treatment-in-patients-with-psoriasis-in-the-european-union-a-systematic-review-of-the-literature
#12
I Belinchón, R Rivera, C Blanch, M Comellas, L Lizán
BACKGROUND AND OBJECTIVE: Adherence to treatment in patients with psoriasis is often poor. An investigation of patient preferences and satisfaction with treatment may be important, based on the expected correlation with therapy compliance. This paper aims to examine and describe the current literature on patient preferences, satisfaction and adherence to treatment for psoriasis in the European Union (EU). METHODS: Electronic searches were conducted using PubMed, ISI Web of Knowledge, Scopus, Spanish databases and Google Scholar...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27894789/cardiovascular-event-risk-assessment-in-psoriasis-patients-treated-with-tumor-necrosis-factor-%C3%AE-inhibitors-versus-methotrexate
#13
Jashin J Wu, Annie Guérin, Murali Sundaram, Katherine Dea, Martin Cloutier, Parvez Mulani
BACKGROUND: Psoriasis is associated with increased risk for cardiovascular disease. OBJECTIVE: To compare major cardiovascular event risk in psoriasis patients receiving methotrexate or tumor necrosis factor-α inhibitor (TNFi) and to assess TNFi treatment duration impact on major cardiovascular event risk. METHODS: Adult psoriasis patients with ≥2 TNFi or methotrexate prescriptions in the Truven MarketScan Databases (Q1 2000-Q3 2011) were classified as TNFi or methotrexate users...
October 26, 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27892584/a-short-history-of-phototherapy-vitamin-d-and-skin-disease
#14
Paul Jarrett, Robert Scragg
The earliest record between sun exposure and skin disease goes back five millennia to the ancient Egyptians. The modern scientific era of medical light therapy and skin diseases started in 1877 when Downs and Blunt reported that exposure to light inhibited fungal growth in test tubes. Continuing research generated a growing medical interest in the potential the effects of light to treat and cure skin diseases considered as parasitic. This culminated in the awarding of the 1903 Nobel Prize in Medicine to Niels Finsen for his pioneering work showing that light could successfully treat cutaneous mycobacterium tuberculosis (lupus vulgaris), a disfiguring disorder common at the time...
November 28, 2016: Photochemical & Photobiological Sciences
https://www.readbyqxmd.com/read/27889959/fumaric-acid-esters-attenuate-secondary-degeneration-following-spinal-cord-injury
#15
Marika Cordaro, Giovanna Casili, Irene Paterniti, Salvatore Cuzzocrea, Emanuela Esposito
Spinal cord injury (SCI) causes permanent changes in motor, sensory and autonomic functions. Unfortunately, there are not a stable cures and current treatments include surgical decompression, methylprednisolone and hemodynamic control that lead to modest function recovery. Fumaric acid esters (FAEs) were firstly used in the management of an immunological skin disorder, such as psoriasis. Because of their potent anti-inflammatory effects, they have been introduced in multiple sclerosis. Investigation shown not only anti-inflammatory, but also supposed neuroprotective mechanism of action...
November 27, 2016: Journal of Neurotrauma
https://www.readbyqxmd.com/read/27889292/short-and-long-term-safety-outcomes-with-ixekizumab-from-7-clinical-trials-in-psoriasis-etanercept-comparisons-and-integrated-data
#16
Bruce Strober, Craig Leonardi, Kim A Papp, Ulrich Mrowietz, Mamitaro Ohtsuki, Robert Bissonnette, Laura K Ferris, Carle Paul, Mark Lebwohl, Daniel K Braun, Lotus Mallbris, Stefan Wilhelm, Wen Xu, Anders Ljungberg, Nayan Acharya, Kristian Reich
BACKGROUND: Safety of biologics is important when treating patients with psoriasis. OBJECTIVE: We sought to determine the safety of ixekizumab in psoriasis. METHODS: Integrated safety data are presented from a 12-week induction period, a 12- to 60-week maintenance period, and from all ixekizumab-treated patients from 7 clinical trials. Exposure-adjusted incidence rates (IRs) per 100 patient-years are reported. RESULTS: Overall, 4209 patients received ixekizumab (total exposure: 6480 patient-years)...
November 23, 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27888159/transmembrane-tnf-alpha-reverse-signaling-leading-to-tgf-beta-production-is-selectively-activated-by-tnf-targeting-molecules-therapeutic-implications
#17
REVIEW
Zsuzsa Szondy, Anna Pallai
Tumor necrosis factor (TNF)-α is a potent pro-inflammatory cytokine exerting pleiotropic effects on various cell types. It is synthesized in a precursor form called transmembrane TNF-α (mTNF-α) which, after being processed by metalloproteinases, is released in a soluble form to mediate its biological activities through Type 1 and 2 TNF receptors in TNF receptor expressing cells. In addition to acting in soluble form, TNF-α also acts in the transmembrane form both as a ligand by activating TNF receptors, as well as a receptor that transmits outside-to-inside (reverse) signals back into mTNF-α bearing cells...
November 22, 2016: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/27887675/clinical-efficacy-and-safety-of-ixekizumab-for-treatment-of-psoriasis
#18
A Azevedo, T Torres
Psoriasis is a common, chronic, inflammatory skin disorder with a physical and emotional burden. Emerging evidence suggests that IL17-A is a key cytokine in the immunopathogenesis of psoriasis. Ixekizumab is a humanized IgG4 monoclonal antibody that acts by neutralizing IL-17A. Data from Phase I-III studies reveal that ixekizumab is highly effective in treating patients with moderate-to-severe plaque psoriasis. A large proportion of patients receiving ixekizumab achieved or maintained complete or near complete resolution of psoriatic lesions with an acceptable safety profile through week 60...
November 22, 2016: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/27885553/biosimilars-for-the-treatment-of-chronic-inflammatory-diseases-a-systematic-review-of-published-evidence
#19
REVIEW
Ira Jacobs, Danielle Petersel, Leah Isakov, Sadiq Lula, K Lea Sewell
BACKGROUND: Clinicians are required to assimilate, critically evaluate, and extrapolate information to support appropriate use of biosimilars across indications. OBJECTIVES: The objective of this study was to systematically collate all published data in order to assess the weight (quantity and quality) of available evidence for each molecule and inform and support healthcare decision-making in chronic inflammatory diseases. METHODS: MEDLINE(®), EMBASE(®), and ISI Web of Science(®) were searched to September 2015...
December 2016: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/27883996/phototherapy-with-narrow-band-uvb-in-adult-guttate-psoriasis-results-and-patient-assessment
#20
Montserrat Fernández-Guarino, Sonsoles Aboín-González, Diana Velázquez, Lucia Barchino, Natividad Cano, Pablo Lázaro
BACKGROUND: Acute guttate psoriasis (AGP) is a distinctive clinical entity with good response to treatment with narrow-band ultraviolet B (NB-UVB). OBJECTIVE: To investigate the results of NB-UVB phototherapy in adult patients with adult guttate psoriasis. MATERIAL AND METHODS: We carried out a prospective, open, and observational study. Patients over 18 years with more than 5% of body surface area affected were included. The PASI was assessed prior to and after treatment...
November 25, 2016: Dermatology: International Journal for Clinical and Investigative Dermatology
keyword
keyword
60126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"